Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Santos C.; Azuara D.; Vieitez J. M.; Paez D.; Falco E.; Elez E.; Lopez-Lopez C.; Valladares M.; Robles-Diaz L.; Garcia-Alfonso P.; Buges C.; Duran G.; Salud A.; Navarro V.; Capella G.; Aranda E.; Salazar R.; Ruiz de Mena I.; Rodriguez S.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

【24h】

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

机译：KRA，NRAS，BRAF和PIK3CA高敏感性基因分型对Panitumumab Plus folfiri的超级选择转移性结肠直肠癌患者的高敏感性基因分型研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations because benefits of anti-EGFR therapies may depend on certain sensitivity thresholds. We assessed whether ultra-selection of patients using a high-sensitive digital PCR (dPCR) to determine KRAS, NRAS, BRAF and PIK3CA status can improve clinical outcomes of panitumumab plus FOLFIRI.

机译：背景：几项研究表明，准确定量不仅克拉斯和其他低丰富突变的重要性，因为抗EGFR疗法的益处可能取决于某些灵敏度阈值。我们评估了使用高敏感数码PCR（DPCR）的患者的超选择是否确定KRAS，NRAS，BRAF和PIK3CA状态可以改善Panitumumab Plus Folfiri的临床结果。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2019年第5期|共8页
作者
Santos C.; Azuara D.; Vieitez J. M.; Paez D.; Falco E.; Elez E.; Lopez-Lopez C.; Valladares M.; Robles-Diaz L.; Garcia-Alfonso P.; Buges C.; Duran G.; Salud A.; Navarro V.; Capella G.; Aranda E.; Salazar R.; Ruiz de Mena I.; Rodriguez S.;
展开▼
作者单位

Inst Catala Oncol Oncobell Program IDIBELL Translat Res Lab Lhospitalet De Llobregat Spain;

Inst Catala Oncol Oncobell Program IDIBELL Translat Res Lab Lhospitalet De Llobregat Spain;

Hosp Univ Cent Asturias Dept Med Oncol Oviedo Spain;

Hosp Santa Creu &

Sant Pau Dept Med Oncol Barcelona Spain;

Hosp Son Llatzer Dept Med Oncol Palma De Mallorca Spain;

Hosp Valle De Hebron Dept Med Oncol Barcelona Spain;

Hosp Univ Marques de Valdecilla Dept Med Oncol Santander Spain;

Hosp Univ A Coruna Dept Med Oncol La Coruna Spain;

Hosp Univ 12 Octubre Dept Med Oncol Madrid Spain;

Hosp Gen Univ Gregorio Maranon Dept Med Oncol Madrid Spain;

Hosp Badalona Germans Trias &

Pujol Dept Med Oncol Inst Catala Oncol Badalona Spain;

Hosp Univ Virgen de la Victoria Dept Med Oncol Malaga Spain;

Hosp Arnau Vilanova Dept Med Oncol Lleida Spain;

Inst Catala Oncol Clin Res Unit Lhospitalet De Llobregat Spain;

Inst Catala Oncol Oncobell Program IDIBELL Translat Res Lab Lhospitalet De Llobregat Spain;

Univ Cordoba CIBERONC Hosp Univ Reina Sofia Dept Med Oncol IMIBIC Cordoba Spain;

Inst Catala Oncol Oncobell Program IDIBELL Translat Res Lab Lhospitalet De Llobregat Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
digital PCR; FOLFIRI; metastatic colorectal cancer; panitumumab; patient selection; PCR;

机译：Digital PCR;Folfiri;转移性结肠直肠癌;Panitumumab;患者选择;PCR;

相似文献

外文文献
中文文献
专利

1. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial [J] . Santos C., Azuara D., Vieitez J. M., Annals of oncology: official journal of the European Society for Medical Oncology . 2019,第5期

机译：KRA，NRAS，BRAF和PIK3CA高敏感性基因分型对Panitumumab Plus folfiri的超级选择转移性结肠直肠癌患者的高敏感性基因分型研究
2. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: A phase II trial by the Gruppo Oncologico Nord Ovest (GONO) [J] . FornaroL., LonardiS., MasiG., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第8期

机译：FOLFOXIRI联合帕尼单抗作为四联野生型（KRAS，NRAS，HRAS，BRAF）转移性结直肠癌患者的一线治疗：Gruppo Oncologico Nord Ovest（GONO）的II期试验
3. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer [J] . Hecht J. Randolph, Cohn Allen, Dakhil Shaker, Clinical colorectal cancer . 2015,第2期

机译：SPIRITT：帕尼单抗联合FOLFIRI和贝伐单抗联合FOLFIRI作为不可切除野生型KRAS转移性结直肠癌患者的二线治疗的随机，多中心，II期研究
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. A randomized Phase II clinical study of combining panitumumab and bevacizumab plus irinotecan 5-fluorouracil and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation [O] . Yuguo Liu, Lijuan Luan, Xingli Wang 2015

机译：帕尼单抗和贝伐单抗联合伊立替康5-氟尿嘧啶和亚叶酸钙（FOLFIRI）联合FOLFIRI作为二线治疗转移性结直肠癌和KRAS突变患者的第二阶段随机临床研究
7. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer [O] . Peeters, Marc, Oliner, Kelly S., Price, Timothy J., 2015

机译：帕尼单抗联合FOLFIRI与单独FOLFIRI作为转移性结直肠癌二线治疗的帕尼单抗III期研究中的KRAS / NRAS突变分析

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

摘要

著录项

相似文献

相关主题

期刊订阅